

Clinical Study

Urinary Eosinophil Protein X in Childhood Asthma: Relation with Changes in Disease Control and Eosinophilic Airway Inflammation

Marianne Nuijsink,¹ Wim C. J. Hop,² Peter J. Sterk,³
Eric J. Duiverman,⁴ and Johan C. De Jongste⁵

¹ Department of Pediatric Respiratory Medicine, Juliana Children's Hospital, HAGA Teaching Hospital, P.O. Box 60605, 2506 LP, The Hague, The Netherlands

² Department of Biostatistics, Erasmus University Medical Centre, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands

³ Department of Respiratory Medicine, Academic Medical University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands

⁴ Department of Pediatric Respiratory Medicine, Beatrix Children's Hospital, University Medical Centre Groningen, P.O. Box 30001, 9700 RB, Groningen, The Netherlands

⁵ Department of Pediatric Respiratory Medicine, Sophia Children's Hospital, Erasmus University Medical Centre, P.O. Box 2060, 3000 CB, Rotterdam, The Netherlands

Correspondence should be addressed to Johan C. De Jongste; j.c.dejongste@erasmusmc.nl

Received 7 November 2012; Accepted 24 December 2012

Academic Editor: Helen C. Steel

Copyright © 2013 Marianne Nuijsink et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The aim of this study was to assess cross-sectional and longitudinal correlations between uEPX and other markers of asthma control and eosinophilic airway inflammation. *Methods.* We measured uEPX at baseline, after 1 year and after 2 years in 205 atopic asthmatic children using inhaled fluticasone. At the same time points, we assessed symptom scores (2 weeks diary card), lung function (forced expiratory volume in one second (FEV₁)), airway hyperresponsiveness (AHR), and percentage eosinophils in induced sputum (% eos). *Results.* We found negative correlations between uEPX and FEV₁ at baseline ($r = -0.18$, $P = 0.01$), after 1 year ($r = -0.25$, $P < 0.01$) and after 2 years ($r = -0.21$, $P = 0.02$). Within-patient changes of uEPX showed a negative association with FEV₁ changes (at 1 year: $r = -0.24$, $P = 0.01$; at 2 years: $r = -0.21$, $P = 0.03$). Within-patient changes from baseline of uEPX correlated with changes in % eos. No relations were found between uEPX and symptoms. *Conclusion.* In this population of children with atopic asthma, uEPX correlated with FEV₁ and % eos, and within-subjects changes in uEPX correlated with changes in FEV₁ and % eos. As the associations were weak and the scatter of uEPX wide, it seems unlikely that uEPX will be useful as a biomarker for monitoring asthma control in the individual child.

1. Introduction

Eosinophilic protein X is produced by activated eosinophils and can be measured in blood, stools, and urine (uEPX) [1, 2]. Elevated uEPX has been reported in asthmatics with or without allergy [3, 4], with great overlap between healthy controls and asthmatics [5, 6]. A relation with asthma symptoms and lung function has been shown, and uEPX increases significantly during asthma exacerbations [7–9]. A reduction in uEPX has been reported after starting inhaled

corticosteroids [10]. Therefore, it has been suggested that measuring urinary EPX may be useful for monitoring the effect of ICS in asthma [3, 10, 11].

Since measuring uEPX is completely noninvasive and independent of patient's cooperation, it has the potential to be a feasible tool in asthma management in young children. Several studies have demonstrated cross-sectional correlations between uEPX and conventional clinical markers of asthma control and airway inflammation [3, 4, 12]. Previously, we reported these cross-sectional data measured

at baseline in part of the present study population [13]. Data on longitudinal changes in uEPX within subjects compared to changes in markers of asthma control or airway inflammation were examined in only one study in 14 children [3].

We analysed cross-sectional and longitudinal uEPX data from a long-term follow-up study in children with atopic asthma [14]. We hypothesised that changes in uEPX would be related to changes eosinophilic airway inflammation and could provide information that is additional to symptoms and lung function.

2. Methods

2.1. Subjects. Asthmatic children took part in a randomised controlled multicentre trial (CATO: Children Asthma Therapy Optimal) reported in detail previously [14]. Briefly, 288 children with a documented clinical history of moderately severe asthma were recruited from 15 paediatric clinics including 7 university hospitals in the Netherlands. All patients had a positive, class 1, or more radioallergosorbent test result for one or more airborne allergens.

During a run-in phase, all patients were treated with 100 or 250 μg fluticasone bid depending on their equivalent treatment before the study. Children were selected on the basis of symptoms and/or AHR, and 210 children were randomised to a reference strategy (adjustment of treatment on symptom score) or an AHR strategy (treatment adjusted on the basis of AHR and symptom score). During the 2-year follow-up study, 3 monthly visits were performed. At each visit symptoms scores (diary card over the last 2 weeks), forced expiratory volume in one second (FEV_1), and methacholine challenge results were obtained, and medication (five levels: fluticasone 100 or 200 μg per day or fluticasone/salmeterol 200/100, 500/100, or 1000/100 μg per day (Flixotide Diskus or Seretide Diskus, GlaxoSmithKline, UK) adjusted according to the algorithms of the reference- and AHR strategy.

For the present study, "baseline" is defined as the moment of randomisation for the CATO study.

2.2. Symptom Scores. Patients filled in a diary card daily during 2 weeks before each 3-month visit. Cough, shortness of breath, and wheezing during night and day were recorded on a 4 point scale (0 = no symptoms to 3 = severe symptoms interfering with activity or sleep) [15]. The percentage of symptom-free days defined as score 0 for cough, wheeze, and shortness of breath was calculated.

2.3. AHR and Spirometry. were measured during each clinic visit [16]. Study medication was stopped 36 hours before lung function and AHR testing. AHR was tested by methacholine challenge using a dosimeter method [17]. The provocation dose causing a 20% fall in FEV_1 from baseline (PD_{20}) was calculated from a log dose-response plot by linear interpolation.

2.4. Sputum Induction and Processing. Sputum induction was attempted in 8 of the 15 participating centres. Sputum was induced according to a standardised method by inhaling an aerosol of hypertonic sodium chloride 4.5% w/v [18, 19].

Differential cell counts of cytopspins were performed and samples containing more than 80% squamous cells were excluded from the analysis [18].

2.5. Urinary Eosinophil Protein X. Spot samples of urine were collected at randomisation (= baseline), after a treatment period of 1 year, and after 2 years (the end of the study), and immediately stored at -20°C . EPX was determined using a commercial enzyme-linked immunosorbent assay (ELISA) for human EPX in 50-fold diluted samples (Medical and Biological Laboratories, Nakaku Nagoya, Japan). The assay's sensitivity was 0.62 ng/mL. Urinary creatinine levels were measured by the alkaline picrate method (Roche, Mannheim, Germany). Urinary EPX concentrations were expressed as μg per mmol creatinine.

2.6. Statistical Analysis. Repeated measurements Anova was used to evaluate associations between the various markers and uEPX levels. The same method was used to assess changes from baseline. With this method (SAS PROC MIXED) the information about the associations at the different study time points can be combined and the method allows for uEPX not being available at all three time points for each patient. In these analyses, uEPX values, % eosinophils in sputum, and fluticasone doses were transformed logarithmically in order to get approximate normal distributions and to reduce the effect of outlying observations, and consequently results for these parameters are expressed as geometric means. Percentage eosinophil values equal to 0 were replaced by 0.1% in order to allow the logarithmic transformation. In a substantial part of the study population, especially at time points T1 and T2, PD_{20} was higher than the highest dose methacholine used (1570 μg). For that reason PD_{20} data were arbitrarily dichotomized in non-AHR ($\text{PD}_{20} > 300 \mu\text{g}$) and AHR ($\text{PD}_{20} < 300 \mu\text{g}$). Correlation coefficients calculated at the different time points are Spearman's rank correlations. $P = 0.05$ (two-sided) was considered the limit of significance.

3. Results

Urinary EPX was measured at least once in 205 children. Patient characteristics at baseline are given in Table 1. In total 461, uEPX samples were analysed during the study. During the 2-year treatment period, the geometric mean uEPX significantly decreased from 159 $\mu\text{g}/\text{mmol}$ to 104 $\mu\text{g}/\text{mmol}$ ($P < 0.001$) (Figure 1). Anova showed a significant treatment effect after 1 year: in the AHR strategy group, uEPX had decreased significantly more than in the reference strategy group, with a 29% lower geometric mean EPX level at that time point ($P = 0.03$). No treatment effect was found at year 2 ($P = 0.26$). Further analysis showed that at 1 year, there was a significant fluticasone dose effect, and this effect was not found at baseline or at year 2. At 1 year a twofold higher dose was associated with a 25% lower uEPX level (95% CI: 15%–34%; $P < 0.001$). Children treated according to the AHR strategy had received significantly higher doses of fluticasone at 1 year (geometric means 580 versus 412 $\mu\text{g}/\text{day}$; Mann-Whitney test, $P = 0.01$). After adjustment for the

TABLE 1: Characteristics of the 205 children at baseline.

Age (y)	10.4 [6.4–16.8]
Gender (m/f)	118/87
Daily dose fluticasone 200 μg /500 μg	116/89
uEPX ($\mu\text{g}/\text{mmol}$ creatinine) ($n = 180$)	184 (2–3114)
Symptom-free days (%)	50 (0–100)
FEV ₁ (% pred)	97 (56–136)
PD ₂₀ methacholine (μg)	72 (1–>1570.0 [#])
Sputum eosinophils (%) ($n = 49$) [†]	1 (0–72)

Values are median (range).

FEV₁: forced expiratory volume in 1 second; PD₂₀ methacholine: provocative dose of methacholine causing FEV₁ fall 20% from baseline.

[#] 12 children had not reached the 20% fall at the highest dose of 1570 μg .

[†] 79 patients had a total of 127% eos measurements combined with an uEPX measurement, and in 49 of these a baseline measurement was available.

Baseline characteristics form part of this group have been published previously in a cross-sectional study by Nuijsink et al. [13].




FIGURE 1: uEPX levels. Geometric mean uEPX (per mmol creatinine) levels with 95 percent confidence intervals by measurement visit (Anova estimates). T0: baseline; T1: after a treatment period of 1 year; T2: after a treatment period of 2 years. T1 versus T0: $P = 0.01$; T2 versus T1: $P = 0.18$; T2 versus T0: $P < 0.001$.

higher dose using Anova, no significant treatment effect remained.

3.1. Urinary EPX versus Parameters of Asthma Control (Tables 2 and 3). No correlations were found between uEPX and the percentage symptom-free days or changes in uEPX and changes in percentage symptom-free days. Anova also did not show significant associations. Cross-sectional analysis showed weak negative correlations of the levels of uEPX and FEV₁ (baseline: $r = -0.18$, $P = 0.02$; at 1 year: $r = -0.25$, $P = 0.002$; at 2 years: $r = -0.21$, $P = 0.016$, resp.). Anova showed

TABLE 2: Correlations between uEPX and clinical markers of asthma.

		r	P value
Symptom-free days (%)	T0	-0.04	0.96
	T1	0.03	0.68
	T2	0.09	0.34
FEV ₁ (% pred)	T0	-0.18	0.01
	T1	-0.25	<0.01
	T2	-0.22	0.02
Sputum eosinophils (%)	T0	0.19	0.19
	T1	0.19	0.20
	T2	0.51	<0.01
PD ₂₀ methacholine (μg)	T0	-0.14	0.08
	T1	-0.20	0.02
	T2	-0.14	0.14

T0: at baseline; T1: after a treatment period of 1 year; T2: after a treatment period of 2 years; FEV₁: forced expiratory volume in 1 second. Numbers evaluated for sputum eosinophils at T0, T1, and T2 are 49, 45, and 33, respectively. Data shown represent Spearman rank correlation coefficients. Correlations at baseline (T0) in part of this group have been published previously in a cross-sectional study (Nuijsink et al. [13]).

TABLE 3: Correlations between the changes from baseline in uEPX and changes in clinical markers of asthma control.

		r	P value
Symptom-free days (%)	T1	-0.06	0.53
	T2	0.10	0.32
FEV ₁ (% pred)	T1	-0.24	0.01
	T2	-0.21	0.03
Sputum eosinophils (%)	T1	0.10	0.64
	T2	0.40	0.11

T0: at baseline; T1: after a treatment period of 1 year; T2: after a treatment period of 2 years. FEV₁: forced expiratory volume in 1 second. The individual changes from baseline of uEPX and % eos are expressed as ratios. For FEV₁ and symptom-free days, the changes are expressed as the absolute differences of the measured percentages. Numbers evaluable for the change from baseline of % eos at T1 and T2 are 23 and 17, respectively. Data shown are Spearman rank correlations.

that the significant associations did not differ between the three time points and adjusting for ICS dose did not change this. Also the changes from baseline of uEPX and FEV₁ were significantly related with each other (at 1 year $r = -0.24$, $P = 0.01$ and at 2 years; $r = -0.21$, $P = 0.03$) (Figure 2). As compared to baseline, a tenfold increase in uEPX was associated with a decrease of FEV₁ (% pred) of 2.8 percentage points (95% CI: 0.3 to 5.3; $P = 0.026$) and this decrease did not significantly differ between the two time points ($P = 0.65$). A similar result was found when changes from the previous assessment were evaluated.

At all visits, uEPX levels were higher in patients with AHR (PD₂₀ methacholine < 300 μg methacholine) than in patients without AHR. At 1 year this difference was statistically significant, with 13% higher uEPX in patients with AHR




FIGURE 2: Scatterplot of within-patient changes from baseline in forced expiratory volume in 1 second versus changes in uEPX. Squares and the solid regression line pertain to changes between baseline and 1-year-followup; asterisks and the dashed line represent changes between baseline and 2 years. Changes of uEPX are shown as ratios; changes of FEV₁ are shown as absolute differences of percentage predicted values.

($P = 0.006$) ($P = 0.08$, $P = 0.10$, resp., at baseline and after 2 years treatment). This effect remained after adjustment for dose. With regard to percentage eosinophils in sputum a significant correlation with uEPX was found at 2 years ($r = 0.51$, $P < 0.001$, $n = 33$). Anova showed a significant overall association between uEPX and percentage sputum eosinophils. A twofold higher value of sputum eosinophils was associated with a 14% increased value of uEPX (95% CI: 6%–22%; $P < 0.001$), and this relation did not significantly differ between the 3 time points ($P = 0.11$), nor was the relation affected by ICS dose. Although changes from baseline of uEPX and percentage sputum eosinophils did not significantly correlate with each other at the separate time points, a significant relation was found combining both time points using Anova. A within-patient doubling of sputum eosinophils was associated with a mean increase of uEPX of 16% (95% CI: 0.1%–36%; $P = 0.049$), and the ICS dose did not affect this relation. The individual variations however are large (Figure 3).

4. Discussion

We prospectively assessed changes in uEPX in relation to changes in asthma control within subjects over an observation period of 2 years. We found in atopic asthmatic children that changes in uEPX measured after 1 and 2 years related significantly with changes in FEV₁ and % sputum eosinophils, but not with changes in symptoms. Changes in uEPX correlated with changes in ICS dose.

Conflicting data have been reported about cross-sectional relationships between uEPX and FEV₁. Previously we




FIGURE 3: Scatterplot of within-patient changes from baseline in uEPX versus changes in percentage sputum eosinophils. Squares and the solid regression line pertain to the changes between baseline and 1 year ($n = 23$); asterisks and the dashed line represent changes between baseline and 2 years ($n = 17$). Changes of uEPX and percentage sputum eosinophils are both shown as ratios.

described the results of cross-sectional analysis at baseline in the present study population [13]. We found a weak inverse correlation between uEPX and FEV₁. With the present study, we confirmed the relation between uEPX and FEV₁ at different time points. Moreover, we showed that changes in uEPX and changes FEV₁ were related. This is in line with the significant correlation between these parameters found by Lugosi et al. in 14 asthmatic children [3]. However the interval of their measurements was much shorter (1–2 months). It has been shown that correlations between eosinophilic airway inflammation and lung function are weak and may only reach significance in large populations [4, 6, 20, 21]. Clearly FEV₁ is dependent on many more factors than eosinophilic inflammation alone.

The correlation between uEPX and sputum eosinophils was weak, and this is in line with the relations between sputum ECP, sputum eosinophils, and uEPX described by Mattes et al. [12]. Weak correlations seem to be the rule when different markers of eosinophilic inflammation are compared [22]. Moreover, uEPX is secreted by activated eosinophils, and it is therefore possible that uEPX provides information about eosinophil activation rather than numbers.

We found no relation between uEPX and symptoms. A significant relation between uEPX and symptoms has been described during acute asthma exacerbations, spontaneously or provoked by ICS withdrawal [23]. Also, significantly higher uEPX levels were found in symptomatic asthmatic children than in asymptomatic children [1, 3, 4]. However, a 6-month follow-up study in 14 children with mild asthma found, no significant association was found [9]. So the severity of symptoms should be taken into account when correlating uEPX and symptoms. In our study population, the

symptom scores were low and this may explain the apparent discrepancy with these previous studies. It could well be that relations between uEPX and parameters of asthma control could have been influenced by other factors as well, including seasonal variations, severity of allergy, and asthma and atopic dermatitis [24, 25]. The use of varying doses of ICS is another possibility, for which we have corrected.

What are the clinical implications of our findings? As uEPX does not correlate with symptoms, but does correlate with sputum eosinophils, we could argue that uEPX might provide additional information on activity of eosinophilic airway inflammation. However, the correlations were weak and the scatter of individual uEPX values wide. Therefore, it seems unlikely that uEPX will be useful as a biomarker for monitoring asthma in the individual child.

Acknowledgments

The authors would like to thank Pieter S. Hiemstra for guidance and advice on cellular and molecular assays, Bram van der Linden for technical assistance of uEPX analysis, H. C. R. Vermey for measuring urinary creatinine levels, and Hilly van der Veen for counting sputum cytopins slides. The role of the funding source is as follows: this study was initiated and designed by the investigators (CATO study group). Glaxo-SmithKline donated study medication. Representatives of the company reviewed and commented on the protocol but made no other contributions to its design, conduct, interpretation, or presentation. Members of the CATO study group are as follows: Department of Pediatric Respiratory Medicine, Haga Hospital/Juliana Children's Hospital, The Hague (M. Nuijsink, MD, J. M. Kouwenberg MD). Department of Epidemiology and Biostatistics, Erasmus University Medical Center, Rotterdam (W. C. J. Hop, PhD). Department of Respiratory Medicine, Academic Medical Centre, University, Amsterdam (Prof. P. J. Sterk, PhD). Leiden University Medical Center, Leiden (E. R. V. M. Rijkers-Mutsaerts MD). Department of Pediatric Respiratory Diseases, University Medical Center Groningen (Prof. E. J. Duiverman, MD and PhD). Department of Pediatric Respiratory Medicine, Erasmus University Medical Center/Sophia Children's Hospital, Rotterdam (Prof. J. C. de Jongste, MD, and PhD). Asthma Center Heideheuvel, Hilversum (O. H. van der Baan-Slootweg MD, E. E. M. van Essen-Zandvliet MD and PhD). Flevo Hospital, Almere (N. J. van den Berg MD and PhD). Prof. J. M. Boogaard PhD. Isala Klinieken, Zwolle (P. L. P. Brand MD and PhD, R. J. Roorda MD and PhD, A. W. A. Kamps MD and PhD). Medical Center, Alkmaar (G. Brinkhorst MD). VU Medical Center, Amsterdam (J. E. Dankert-Roelse MD and PhD, A. F. Nagelkerke MD). Maxima Medical Center, Veldhoven (R. van Gent MD and PhD). Maasland Hospital, Sittard (J. W. C. M. Heijns MD). University Hospital Maastricht (J. J. E. Hendriks MD and PhD, Q. Jöbsis MD and PhD). University Medical Center/Wilhelmina Children's Hospital, Utrecht (J. van der Laag MD, H. J. L. Brackel MD and PhD). Academic Medical Center, Amsterdam (J. C. van Nierop MD). Amphia Hospital, Breda (A. A. P. H. Vaessen-Verberne MD and PhD) all from The Netherlands.

References

- [1] D. Y. Koller, G. Halmerbauer, T. Frischer, and B. Roithner, "Assessment of eosinophil granule proteins in various body fluids: is there a relation to clinical variables in childhood asthma?" *Clinical and Experimental Allergy*, vol. 29, no. 6, pp. 786–793, 1999.
- [2] H. Majamaa, S. Laine, and A. Miettinen, "Eosinophil protein X and eosinophil cationic protein as indicators of intestinal inflammation in infants with atopic eczema and food allergy," *Clinical and Experimental Allergy*, vol. 29, no. 11, pp. 1502–1506, 1999.
- [3] E. Lugosi, G. Halmerbauer, T. Frischer, and D. Y. Koller, "Urinary eosinophil protein X in relation to disease activity in childhood asthma," *Allergy*, vol. 52, no. 5, pp. 584–588, 1997.
- [4] E. Tauber, G. Halmerbauer, T. Frischer et al., "Urinary eosinophil protein X in children: the relationship to asthma and atopy and normal values," *Allergy*, vol. 55, no. 7, pp. 647–652, 2000.
- [5] M. O. Hoekstra, H. Hovenga, J. Gerritsen, and H. F. Kauffman, "Eosinophils and eosinophil-derived proteins in children with moderate asthma," *European Respiratory Journal*, vol. 9, no. 11, pp. 2231–2235, 1996.
- [6] C. Severien, A. Artlich, S. Jonas, and G. Becher, "Urinary excretion of leukotriene E4 and eosinophil protein X in children with atopic asthma," *European Respiratory Journal*, vol. 16, no. 4, pp. 588–592, 2000.
- [7] R. Oosaki, Y. Mizushima, A. Kawasaki, H. Mita, K. Akiyama, and M. Kobayashi, "Correlation among urinary eosinophil protein X, leukotriene E4, and 11-dehydrothromboxane B2 in patients with spontaneous asthmatic attack," *Clinical and Experimental Allergy*, vol. 28, no. 9, pp. 1138–1144, 1998.
- [8] W. K. Kalaaieh and R. Hoilat, "Asthma attack severity and urinary concentration of eosinophil X protein in children," *Allergologia et Immunopathologia*, vol. 30, no. 4, pp. 225–231, 2002.
- [9] C. Wojnarowski, B. Roithner, D. Y. Koller et al., "Lack of relationship between eosinophil cationic protein and eosinophil protein X in nasal lavage and urine and the severity of childhood asthma in a 6-month follow-up study," *Clinical and Experimental Allergy*, vol. 29, no. 7, pp. 926–932, 1999.
- [10] A. Labbe, B. Aublet-Cuvelier, L. Jouaville et al., "Prospective longitudinal study of urinary eosinophil protein X in children with asthma and chronic cough," *Pediatric Pulmonology*, vol. 31, no. 5, pp. 354–362, 2001.
- [11] S. Kristjánsson, I. L. Strannegård, O. Strannegård, C. Peterson, I. Enander, and G. Wennergren, "Urinary eosinophil protein X in children with atopic asthma: a useful marker of antiinflammatory treatment," *Journal of Allergy and Clinical Immunology*, vol. 97, no. 6, pp. 1179–1187, 1996.
- [12] J. Mattes, K. Storm Van's Gravesande, U. Reining et al., "NO in exhaled air is correlated with markers of eosinophilic airway inflammation in corticosteroid-dependent childhood asthma," *European Respiratory Journal*, vol. 13, no. 6, pp. 1391–1395, 1999.
- [13] M. Nuijsink, W. C. J. Hop, P. J. Sterk, E. J. Duiverman, P. S. Hiemstra, and J. C. De Jongste, "Urinary eosinophil protein X in children with atopic asthma," *Mediators of Inflammation*, vol. 2007, Article ID 49240, 2007.
- [14] M. Nuijsink, W. C. J. Hop, P. J. Sterk, E. J. Duiverman, and J. C. De Jongste, "Long-term asthma treatment guided by airway

- hyperresponsiveness in children: a randomised controlled trial," *European Respiratory Journal*, vol. 30, no. 3, pp. 457–466, 2007.
- [15] A. A. P. H. Verberne, C. Frost, R. J. Roorda et al., "One year treatment with salmeterol compared with beclomethasone in children with asthma," *American Journal of Respiratory and Critical Care Medicine*, vol. 156, no. 3 I, pp. 688–695, 1997.
- [16] P. H. Quanjer, G. J. Tammeling, J. E. Cotes, O. F. Pedersen, R. Peslin, and J. C. Yernault, "Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal," *The European Respiratory Journal*, vol. 16, pp. 5–40, 1993.
- [17] D. Birnie, G. W. S. Thoe Schwartzberg, W. C. J. Hop, E. E. M. Van Essen-Zandvliet, and K. F. Kerrebijn, "Does the outcome of the tidal breathing and dosimeter methods of assessing bronchial responsiveness in children with asthma depend on age?" *Thorax*, vol. 45, no. 3, pp. 199–202, 1990.
- [18] A. Efthimiadis, A. Spanevello, Q. Hamid et al., "Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation," *European Respiratory Journal*, vol. 20, no. 37, pp. 19s–23s, 2002.
- [19] J. C. C. M. In't Veen, H. W. F. M. De Gouw, H. H. Smits et al., "Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma," *European Respiratory Journal*, vol. 9, no. 12, pp. 2441–2447, 1996.
- [20] R. Louis, L. C. K. Lau, A. O. Bron, A. C. Roldaan, M. Radermecker, and R. Djukanović, "The relationship between airways inflammation and asthma severity," *American Journal of Respiratory and Critical Care Medicine*, vol. 161, no. 1, pp. 9–16, 2000.
- [21] L. M. Van Den Toorn, S. E. Overbeek, J. C. De Jongste et al., "Airway inflammation is present during clinical remission of atopic asthma," *American Journal of Respiratory and Critical Care Medicine*, vol. 164, no. 11, pp. 2107–2113, 2001.
- [22] M. A. Berry, D. E. Shaw, R. H. Green, C. E. Brightling, A. J. Wardlaw, and I. D. Pavord, "The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma," *Clinical and Experimental Allergy*, vol. 35, no. 9, pp. 1175–1179, 2005.
- [23] K. Lönnkvist, C. Hellman, J. Lundahl, G. Halldén, and G. Hedlin, "Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: impact of budesonide treatment and withdrawal," *Journal of Allergy and Clinical Immunology*, vol. 107, no. 5, pp. 812–817, 2001.
- [24] K. Ymar and R. Bjercknes, "Urinary eosinophil protein X in children with atopic dermatitis: relation to atopy and disease activity," *Allergy*, vol. 55, no. 10, pp. 964–968, 2000.
- [25] N. Pucci, E. Lombardi, E. Novembre et al., "Urinary eosinophil protein X and serum eosinophil cationic protein in infants and young children with atopic dermatitis: correlation with disease activity," *Journal of Allergy and Clinical Immunology*, vol. 105, no. 2, pp. 353–357, 2000.